Grossman Adam S sold 42,000 shares of ADMA BIOLOGICS, INC. at $12.00 for −$504k on Nov 5, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
President and CEO
President and CEO
Filed Nov 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$504,000Shares × reported price
Shares traded
42,000Common Stock
Price per share
$12.00Reported price. Read footnotes for ranges.
% of reported position traded
1.99%This security and ownership context
Holdings after
2,070,777Direct
Trade date
Nov 5, 2026Sell
Filed
Nov 5, 2026, 9:05 PM ET1-day reporting delay
Accession
0001140361-26-042166Code S · Transaction 394211
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 2,112,777 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Option exercise105,000$5.40$567,000Trade 394209
Nov 5, 2026Sell105,000$12.00−$1,260,000Trade 394210
Nov 5, 2026Option exercise105,000$0.00$0Trade 394212
4 transaction rows in this filing. Joint filers share the same rows.

ADMA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADMA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −20%1w ago −11%1d ago −11%
Returns since7d +4%30d90d180d1y

Footnotes in full

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. F2: The price reported in Column 4 is the price at which the shares were sold. F3: Includes, as of the transaction date, (i) 282,529 unvested restricted stock units ("RSUs") granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4: (continued from footnote 3) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023, vesting quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F5: (continued from footnote 4) and (v) 1,176,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth. F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden. F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.